News
News
News from 4P Life Ventures, and the transactions that matter in longevity.
Transactions from the last six months across the seven longevity segments: acquisitions, fundraisings, licences and IPOs. Hover over a line to see its segment.
DateCompanyDealAcquirer / investorsAmount
Oct. 2026
Sōlaria BiōClinically validated synbiotics
M&AViomen.d.Source ↗5 · Consumer longevity — ProbioticsSep. 2026
Viking TherapeuticsVK2735 (GLP-1/GIP inj. and oral)
FundraisingPublic offering (shares and convertibles)$575mSource ↗1 · Peptides & GLP-1 — GLP-1 & incretins (pharma)Sep. 2026
Jiangsu Hengrui PharmaceuticalsHRS-1596, GLP-1/GIP oral hebdomadaire
Licence · announcedNovo Nordiskup to $2.6bnupfront $300mSource ↗1 · Peptides & GLP-1 — GLP-1 & incretins (pharma)Sep. 2026
Moonwalk BiosciencessiRNA targeting adipose tissue (MW101, obesity)
FundraisingAlpha Wave, YK Bioventures, Eli Lilly$70mSource ↗1 · Peptides & GLP-1 — Obesity (siRNA)Sep. 2026
UltrahumanSmart ring & health platform
FundraisingQualcomm Ventures, Labcorp, Alpha Wave…$70mSource ↗2 · Diagnostics & biomarkers — WearablesSep. 2026
Nestlé Health Science — consumer VMSNature's Bounty, Puritan's Pride, Nuun
M&A · announcedYellow Wood Partners$1bnSource ↗5 · Consumer longevity — VMS supplementsSep. 2026
CuoripsiPSC-derived cardiomyocyte sheets
FundraisingJICVGI Opportunity Fund No.1 (reserved issue)$19.5mSource ↗6 · Cell therapies — iPSCSep. 2026
HexemBioCell therapy for haematopoietic stem cell rejuvenation
FundraisingDraper Associates (lead), Boost VC…n.d.$15.5m raised to dateSource ↗7 · Ageing biotech — Ageing therapeuticsAug. 2026
Gan & Lee PharmaceuticalsBofanglutide (GZR18), fortnightly GLP-1 – 39 European countries
Licence · announcedMenariniup to €726m≈ $843m; upfront $72mSource ↗1 · Peptides & GLP-1 — GLP-1 & incretins (pharma)Aug. 2026
Hanmi PharmaceuticalHM17321, UCN2 (CRF2) peptide analogue – fat loss with muscle gain
Licence · announcedRocheup to $2.3bnupfront $190mSource ↗1 · Peptides & GLP-1 — Obesity: muscle preservationAug. 2026
Circulate HealthTherapeutic plasma exchange (TPE)
M&AViomen.d.Source ↗3 · Longevity centres — Longevity protocols (plasma exchange)Aug. 2026
ThorneThorne premium supplements, at-home tests
M&A · announcedProcter & Gamble$3.8bnSource ↗5 · Consumer longevity — Premium supplementsAug. 2026
Jamieson WellnessJamieson vitamins, youtheory collagen
M&A · announcedKirin Holdings$1.78bnSource ↗5 · Consumer longevity — VMS supplementsAug. 2026
Epicrispr BiotechnologiesEPI-321, AAV epigenetic therapy (FSHD)
FundraisingOctagon Capital, Janus Henderson, Sanofi Ventures$90mSource ↗7 · Ageing biotech — Epigenetic editingJul. 2026
Function Health100+ biomarker panel on subscription
FundraisingGeneral Catalyst$450mSource ↗2 · Diagnostics & biomarkers — Biomarker panelsJul. 2026
Neko HealthNeko Body Scan (scan corps entier IA)
FundraisingLightspeed, O.G. Venture Partners$700mSource ↗2 · Diagnostics & biomarkers — Whole-body imagingJul. 2026
Oura HealthBague Oura Ring 4 + abonnement
Strategic investmentEli Lilly (equity investment)n.d.Source ↗2 · Diagnostics & biomarkers — WearablesJul. 2026
Huaxia (Qingdao) BiotechnologyAcellular amniotic matrix injection (dark circles / tear trough hollows), in development
Equity stakeImeik Technology (15.64% stake)n.d.Source ↗4 · Regenerative injectables — BiostimulatorsJul. 2026
Insilico MedicinePlateforme Pharma.AI (PandaOmics, Chemistry42)
LicenceTakedaup to $600mupfront and near-term $60mSource ↗7 · Ageing biotech — AI & ageing targetsJul. 2026
Scribe TherapeuticsSTX-1150, in vivo epigenetic silencing of PCSK9 (LDL-C)
IPONasdaq (SCTX)$128.7mSource ↗7 · Ageing biotech — Epigenetic editingJun. 2026
Everlab100+ biomarker panel, AI-driven preventive medicine
FundraisingAirtree, Plural, Left Lane, b2venture$46mAU$65mSource ↗2 · Diagnostics & biomarkers — Biomarker panelsJun. 2026
iRegene TherapeuticsNouvNeu001 (Parkinson's, Phase 2) and NouvNeu004 (MSA), chemically induced iPS cells
FundraisingLuminous Ventures, Apricot Capital$31mSource ↗6 · Cell therapies — iPSCJun. 2026
NewLimitEpigenetic reprogramming of hepatocytes (mRNA)
FundraisingFounders Fund, Thrive, Lilly Ventures$435mvaluation $3.1bnSource ↗7 · Ageing biotech — Epigenetic reprogrammingJun. 2026
GeroAI for ageing targets (Gero)
FundraisingInvestors incl. Melnichek Investments$17mSource ↗7 · Ageing biotech — AI & ageing targetsMay 2026
General ProximityOmniTAC platform (induced-proximity medicines)
FundraisingDaewoong Pharmaceutical, FreeMind Investmentsn.d.Source ↗7 · Ageing biotech — Ageing therapeuticsMay 2026
SignosCGM + AI for weight management / metabolic health
FundraisingGV, Dexcom, 450 Ventures$20mSource ↗2 · Diagnostics & biomarkers — Personalised nutrition / CGMMay 2026
SuppCoSupplement rating and tracking app
M&AFunction Healthn.d.Source ↗5 · Consumer longevity — Apps & distributionMay 2026
Retro BiosciencesRTR242 (autophagy, Alzheimer's), blood stem cells
FundraisingFirst closen.d.valuation $1.8bn pre-moneySource ↗7 · Ageing biotech — Partial reprogrammingMay 2026
LucisPreventive blood check-up, 110+ biomarkers, AI follow-up
FundraisingSingular (lead), General Catalyst, Y Combinator$20mSource ↗2 · Diagnostics & biomarkers — Biomarker panelsAnnounced amounts; licences at maximum value, milestones included. n.d.: not disclosed. Public and signed transactions, selected from the 4PLV database; each line links to its source (company release, regulatory filing or leading press).
Oct.2026
Corporate
Singapore partnership
4P Life Ventures · Asia-Pacific
4P Life Ventures partners with Eric Bonafini, a Singapore-based Strategic Partner, to support its clients with Asia-Pacific and Gulf investors and acquirers, and on the financial structuring of transactions.
Meet the team →Oct.2026
Publication
Longevity M&A & Dynamics
4PLV research · October 2026
4P Life Ventures publishes its study of longevity: why longevity is becoming a market, how big it is and how it is transacted.
Read the summary →30 sept.to 1 Oct. 2026
Conference
International Longevity Summit Madrid
Real Academia Nacional de Medicina, Madrid
4P Life Ventures took part in the International Longevity Summit in Madrid, which brings together researchers, physicians, entrepreneurs, investors and policymakers around ageing research and its translation into clinical practice.
Event website ↗
2-3Sept. 2026
Forum
2060 Longevity Forum
Aix-en-Provence · 2060 Foundation
4P Life Ventures took part in the 2060 Longevity Forum, which brings together investors, founders, scientists and policymakers to build the longevity economy, with one ambition: connecting founders with capital.
Forum website ↗